U.S. Stock Market Midday Update

Polyrizon, down 24.07%, with increased trading volume and no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Stocks with High Trading Volume in the Industry

Amgen up 4.50%. Based on recent key news:

1. On July 25, the European Medicines Agency recommended the withdrawal of Tavneos' approval due to unreliable research data. This event raised market concerns about the safety of Amgen's drugs, but Amgen still has the opportunity to submit supporting data before July 29, causing stock price fluctuations.

2. On July 28, analyst ratings showed Amgen with a hold rating and not included in the recommended buy list. Nevertheless, Amgen's stock price rose, indicating market confidence in its future development.

3. No other significant news recently. The healthcare industry faces regulatory challenges, with noticeable capital inflow.

AbbVie up 3.20%. Based on recent key news:

1. On July 27, the U.S. stock market welcomed a busy week of earnings reports, with multiple companies, including AbbVie, set to announce results, along with the Federal Reserve's interest rate decision, preliminary GDP estimates, June PCE data, and employment cost index. These policy signals, tech company earnings, and inflation data may affect interest rate expectations and valuations, with capital potentially shifting towards large tech, AI infrastructure, and interest rate-sensitive sectors, increasing short-term volatility.

2. On July 25, AbbVie offers an attractive 2.7% yield, a solid pharmaceutical business, and a clear focus on dividends, which boosted investor confidence and drove the stock price up.

3. On July 28, the recent market rebound may trigger "sell the news" volatility, but this should not deter long-term holders. Market capital flows towards large tech and AI sectors, increasing short-term volatility.

Gilead Sciences up 3.07%. Based on recent key news:

1. On July 28, Gilead Sciences' HIV product portfolio performed strongly, with specific sales for HIV reaching $20.8 billion by 2025, a 6% year-over-year increase. This growth reflects the company's market position in HIV treatment, driving the stock price up.

2. On July 23, BMO Capital gave Gilead Sciences a buy rating with a target price set at $120. The positive rating from analysts boosted market confidence, propelling the stock price upward.

3. On July 28, GlaxoSmithKline's Dovato showed comparable efficacy to Gilead's Biktarvy in studies. Despite increased competition, Biktarvy's market performance remains robust, not negatively impacting the stock price. The HIV treatment market is highly competitive with significant growth potential.

Stocks with High Market Capitalization in the Industry

Forte Pharmaceuticals up 1.29%. Based on recent news,

1. On July 28, companies in the industry successfully executed diversification strategies to attract capital, while companies facing pipeline failures quickly made valuation adjustments. This market differentiation led to an increase in the stock price of Futu Pharmaceutical.

2. On July 25, top analysts believed that Futu Pharmaceutical is not one of the best buy stocks currently, despite its rating being a moderate buy. This indicates a weakening of market confidence in Futu Pharmaceutical, yet the stock price still rose.

3. There are no other significant news recently. The diversification strategies of companies in the industry attract capital